GenomelinkSummer 2021Active☆Watch⊞Compare

Genomelink is one of 233 Biotech companies tracked from Berkeley, CA, USA; Remote, on record since 2021. By capital raised it ranks mid-pack (ahead of 67% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst”

DNA App Store

Genomelink is a DNA App Store. If you’ve taken a DNA test from Ancestry or 23andMe, you can upload your data to Genomelink to unlock a wide range of DNA apps: a 2,000+ region ancestry breakdown, insights from 400+ ancient DNA samples, analysis of 350+ genetic traits, unique DNA matches, and more. Explore our latest genealogy app, YourRoots (https://yourroots.com/), which transforms your family tree into an interactive global map visualization. We believe consumer genomics today is where the internet was in the 1990s. Over 50 million people in the U.S. have already tested their DNA, and this number will grow into the billions globally in the coming decades. Genomelink aims to become the default DNA data hub and app store for this genomic future. Our mission: - Build the world’s #1 platform for consumer genomics apps - Help people discover their family roots and unite the world - Create an infruscrucure for consumer genomics

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

No round amounts on record to chart.

No staged rounds to sequence.

Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Benchmarked against 233 companies in Biotech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 67% of sector peers (real $). Modeled value above 67% of peers (estimate).

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Genomelink is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where Genomelink sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at Genomelink, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.